Macular Telangiectasia Type 2: A Comprehensive Review

被引:11
|
作者
Kedarisetti, Kiran Chandra [1 ]
Narayanan, Raja [1 ,2 ,6 ]
Stewart, Michael W. [3 ]
Gurram, Nikitha Reddy [1 ]
Khanani, Arshad M. [4 ,5 ]
机构
[1] LV Prasad Eye Inst, Anant Bajaj Retina Inst, Hyderabad, Telangana, India
[2] Publ Hlth & Econ Res Ctr IHOPE, Indian Hlth Outcomes, Hyderabad, Telangana, India
[3] Mayo Clin, Dept Ophthalmol, Jacksonville, FL USA
[4] Sierra Eye Associates, Dept Clin Res, Reno, NV USA
[5] Univ Nevada, Dept Ophthalmol, Reno, NV USA
[6] L V Prasad Eye Inst, Anant Bajaj Retina Inst, Hyderabad, Telangana, India
来源
CLINICAL OPHTHALMOLOGY | 2022年 / 16卷
关键词
macular telangiectasia type 2; MacTel; CNTF; ciliary neurotrophic factor; OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL NEOVASCULARIZATION SECONDARY; JUXTAFOVEOLAR RETINAL TELANGIECTASIS; INTRAVITREAL BEVACIZUMAB THERAPY; GRID LASER PHOTOCOAGULATION; GROWTH-FACTOR THERAPY; PHOTODYNAMIC THERAPY; SUBFOVEAL NEOVASCULARIZATION; FUNDUS AUTOFLUORESCENCE; FLUORESCEIN-ANGIOGRAPHY;
D O I
10.2147/OPTH.S373538
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Macular telangiectasia Type 2 (MacTel) is a gradually progressive disease that affects the quality of life by impairing both distant and near vision. It had previously been considered a vascular condition, but recent evidence suggests a neurodegenerative etiology, with primary involvement of Muller cells. Retinal pigment epithelium (RPE) hyperplasia and subretinal neovascularization (SNV) are responsible for most of the vision loss in advanced cases. Neurotrophic factors in the non-proliferative phase and intravitreal anti-Vascular Endothelial growth factor (VEGF) in the proliferative phase have shown to retard the progression of the disease. This review will discuss the pathophysiology, clinical features, important diagnostic imaging studies and available treatment options for MacTel.
引用
收藏
页码:3297 / 3309
页数:13
相关论文
共 50 条
  • [1] Macular telangiectasia type 2
    Issa, Peter Charbel
    Gillies, Mark C.
    Chew, Emily Y.
    Bird, Alan C.
    Heeren, Tjebo F. C.
    Peto, Tunde
    Holz, Frank G.
    Scholl, Hendrik P. N.
    PROGRESS IN RETINAL AND EYE RESEARCH, 2013, 34 : 49 - 77
  • [2] OUTCOMES OF MACULAR HOLE SURGERIES FOR MACULAR TELANGIECTASIA TYPE 2
    Karth, Peter A.
    Raja, Sharath C.
    Brown, David M.
    Kim, Judy E.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2014, 34 (05): : 907 - 915
  • [3] Spontaneous Closure of a Macular Hole in Macular Telangiectasia Type 2
    Chandra, Varun
    Merani, Rohan
    Hunyor, Alex P.
    Gillies, Mark
    JOURNAL OF VITREORETINAL DISEASES, 2021, 5 (03) : 275 - 280
  • [4] How Prevalent is Macular Telangiectasia Type 2?
    Chew, Emily Y.
    OPHTHALMIC EPIDEMIOLOGY, 2012, 19 (04) : 183 - 184
  • [5] DIABETIC RETINOPATHY IN TYPE 2 MACULAR TELANGIECTASIA
    Peto, T.
    Abdillahi, H.
    Sallo, F.
    Leung, I.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2010, 20 (03) : 650 - 650
  • [6] Functional characteristics of macular telangiectasia type 2
    Heeren, T. F. C.
    Krueger, E.
    Holz, F. G.
    Issa, P. Charbel
    OPHTHALMOLOGE, 2014, 111 (09): : 829 - 833
  • [7] Metamorphopsia in patients with macular telangiectasia type 2
    Issa, Peter Charbel
    Holz, Frank G.
    Scholl, Hendrik P. N.
    DOCUMENTA OPHTHALMOLOGICA, 2009, 119 (02) : 133 - 140
  • [8] Genetic Background of Macular Telangiectasia Type 2
    Kuncic, Ajda
    Urbancic, Mojca
    Divjak, Darja Dobovsek
    Hudler, Petra
    Debeljak, Natasa
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (02)
  • [9] Dark adaptation in macular telangiectasia type 2
    Tzaridis, Simone
    Hess, Kristina
    Heeren, Tjebo
    Mai, Clarissa
    Herrmann, Philipp
    Issa, Peter Charbel
    Holz, Frank G.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [10] Management of Idiopathic Macular Telangiectasia Type 2
    Khodabande, Alireza
    Roohipoor, Ramak
    Zamani, Javad
    Mirghorbani, Masoud
    Zolfaghari, Hamidreza
    Karami, Shahab
    Modjtahedi, Bobeck S.
    OPHTHALMOLOGY AND THERAPY, 2019, 8 (02) : 155 - 175